Patient Acquisition Marketing for Specialty Clinics and Chains

For a multi-location specialty clinic, patient acquisition is not a brand problem. It is the same problem repeated at every centre, and it is usually lost at the centre with the wrong phone number. Patients search a condition plus a locality and choose from a map result, which means patient acquisition compounds through per-location data integrity rather than through anything that happens at head office.

What has changed is the tactic the whole sector relied on. Since 6 October 2026, the National Medical Commission's advertising guidelines state that a registered medical practitioner "shall not request or share patient testimonials." Review solicitation — the default engine of clinic local SEO in India — is now legally doubtful at best, and in some of its common forms clearly barred.

Truth line: every clinic chain in India is currently running a review campaign that its own compliance counsel has not looked at since 6 October.

What exactly do the new rules say about reviews?

This deserves care, because the position is more graded than either the alarmist or the dismissive reading suggests, and the distinction decides what you can still do on Monday.

Two separate provisions are in play. The guidelines bar a practitioner from requesting or sharing patient testimonials — no qualifier attached. They separately bar soliciting, purchasing, procuring, manipulating or causing to be published fake, paid or misleading patient reviews — where the qualifier does attach. And patient consent, the notice states, "shall not, by itself, make permissible any testimonial, endorsement, promotional patient story."

So the live question is whether a solicited Google review is a testimonial or a review. Reputable coverage reads it both ways. The South First quotes the testimonial prohibition and the fake-or-paid review prohibition as distinct clauses. Medical Buyer reports an "explicit ban on soliciting or sharing patient testimonials, recommendations, endorsements and reviews" for professional promotion, which reads the solicitation bar across both.

I am not going to pretend that is settled, and anyone telling you it is has not read both. What a chain can do is grade its own exposure:

Clearly barred

• Requesting a patient testimonial, in any medium
• Soliciting, buying, procuring, manipulating or publishing fake, paid or misleading reviews or ratings
• Offering any benefit, however small, in exchange for a review
• Buying followers, likes, comments or views
• Manipulating search rankings or algorithms
• Paid ranking of doctors on third-party healthcare platforms
• Paying an agency on a per-lead or per-patient basis

Doubtful — take your own advice before continuing

• Asking a patient, verbally or by automated message, for a genuine public review. This turns on the testimonial question above.
• Reproducing or embedding reviews in your own marketing or on a location page. This is closer to sharing a testimonial than to receiving one, so the risk is higher than for the request itself.
• Asking only satisfied patients. This compounds the manipulation exposure and carries separate platform risk, below.

Reasonably safe

• Collecting internal, non-public feedback for clinical governance and service improvement
• Responding to public reviews in general, non-clinical terms, without confirming that the person was a patient or discussing any condition

That last line matters more than it looks. A public reply saying "thank you for visiting our Indore centre" confirms a care relationship in public, which is a patient-privacy problem under the Digital Personal Data Protection Act, 2023 quite separately from the NMC question.

Google has its own view, and its penalties are automatic

Platform policy runs independently of Indian law. Google's documentation on Business Profile restrictions states that it takes fake and incentivised reviews and ratings very seriously, and that violations can draw several restrictions at once: removal of the offending reviews, blocking new reviews or ratings for a period, unpublishing existing reviews for a period, and displaying a warning on the profile telling consumers that fake reviews were removed.

Read that last penalty against a clinic chain. A public badge on your Business Profile announcing that fake reviews were removed is worse than having no reviews. Google emails the owner before applying a restriction and an appeal is available, but the exposure is a profile-level reputational mark, applied per location.

And there is an Indian standard nobody mentions

The Bureau of Indian Standards published IS 19000:2022, "Online Consumer Reviews — Principles and Requirements for their Collection, Moderation and Publication", announced on 12 December 2022. It sets requirements for review administrators on collecting, moderating and publishing reviews, and it applies not only to platforms but to sellers collecting reviews from their own customers.

It arrived as a voluntary standard. In May 2024 the Department of Consumer Affairs moved toward making it binding through a draft Quality Control Order. If that lands, review practices stop being an ethics question and become a consumer-law question, enforceable against the establishment rather than the doctor.

Three regimes, then, pointing the same way. The honest conclusion is that review velocity is no longer a strategy you can build a chain on.

So what actually compounds instead?

Four layers per centre, each one durable, each one lawful, none of them a review. We call it the Location Integrity Stack, and it is deliberately boring.

Layer 1 — Identity. One correct, verified listing per centre. One name, one address in the format the post office uses, one phone number that rings at that centre, correct hours including the days you are closed, and no duplicates. For a chain that has grown by acquisition this is the whole job: the clinic you bought in 2023 almost certainly still has a listing under its old name with the previous owner's mobile number, and it is competing with your own listing for the same pin.

Layer 2 — Classification. Primary category decides which queries a listing is eligible for at all, and it is the single highest-leverage field in the entire profile. Secondary categories and the services list extend reach. Get the primary category wrong across forty centres and no amount of content or paid media fixes it.

Layer 3 — Proof. Practitioner listings where genuinely public-facing, factual credentials, equipment actually installed at that centre, languages spoken, accessibility, parking. All permitted — the guidelines allow factual facility information. Note the naming trap: a practitioner title like "Dr Sharma — Best Eye Specialist" now fails twice over, once on Google's naming conventions and once on the NMC's rule that superiority claims must be objectively verifiable through a transparent, independently ascertainable method. The compliant title is the real-world name.

Layer 4 — Conversion. The path from map result to confirmed appointment. For most Indian clinics that path is a phone call, which makes this an operations layer as much as a marketing one — covered below.

The reason this stack compounds is that nobody maintains it. Data integrity across thirty or forty centres is unglamorous, invisible when done well, and it is the one asset a competitor cannot buy in a quarter. It is also the thing that local search visibility has always actually rewarded.

How big is the presence problem really?

Bigger than a head-office marketing team imagines, and the listed operators show the scale.

Dr Lal PathLabs' FY25 results report 28.8 million patients served, up from 27.6 million, across 6,607 patient service centres, 298 clinical labs and 12,365 pick-up points, on revenue of ₹2,461 crore, up 10.5%.

That is close to nineteen thousand physical touchpoints. Divide the revenue by the patients and you get roughly ₹855 per patient — my arithmetic, not a disclosed figure, and the point of doing it is to show what kind of business this is. At that ticket size there is no room for persuasion-led marketing. The entire game is being accurately present at the nearest point to the patient, repeated thousands of times.

A chain with thirty centres is running the same problem at a smaller scale, and usually with one person managing it part-time alongside social media.

Why does spend have to be phased per centre?

Because a new centre does not behave like a mature one, and the audited data puts a number on the gap.

Dr Agarwal's Health Care's FY2024-25 annual report discloses that mature facilities, defined as those operating more than three years, contributed 70.7% of revenue, while emerging facilities under three years contributed 29.3% — across 236 operational facilities, 218 in India and 18 across nine African countries. Total income was ₹1,757 crore, up 27.6%, with EBITDA of ₹502 crore at a 28.6% margin.

The volume concentration is worth noting too: 206,545 of 282,326 surgeries were cataract procedures, about 73%. In a chain like that, one procedure drives the demand, which means the content and campaign architecture should be built around that procedure plus locality — not around the brand, and not around the full service list.

The three-year maturity line is the planning implication. Acquisition spend at a new centre should be front-loaded and should be allowed a worse cost per patient than a mature centre, because you are buying a position in a local market rather than this month's appointments. Holding a new centre to the mature network's acquisition cost is how chains starve exactly the locations that need the investment. Measuring that properly means per-centre reporting rather than network-level dashboards, which is the discipline in our note on measuring marketing ROI and in how we approach reporting generally.

One honest gap: no listed operator publishes customer acquisition cost split by channel, or a month-by-month ramp curve for a new centre. Marketing spend as a share of revenue is also not reliably extractable from the statements at the granularity a chain would need. Figures circulating for either are derived by third parties, not disclosed. Build your own baseline from your own centres.

Do patients actually book online, or do they call?

They call. This is the strongest objection to most of what agencies sell clinic chains, and it should change where the money goes.

There is no credible published data on the phone-versus-web-versus-walk-in split for Indian private specialty clinics — the report underlying this article searched for it and found nothing, and I am not going to substitute a vendor's estimate. But the behaviour is not seriously disputed: a patient who finds your centre on a map taps the call button.

The consequence is uncomfortable for marketing teams. If most appointments begin as a phone call, then your conversion rate is set by who answers the phone, how fast, in which language, and whether they can actually see the appointment book for that centre. A redesigned booking form does not touch any of that.

So the conversion layer of the stack is mostly operational work:

• The number on each listing rings at that centre, or into a routing system that knows which centre the patient tapped
• Someone answers within three rings during stated hours, and the stated hours are true
• Whoever answers can book, not just take a message
• Missed calls are logged and called back the same day, because a missed call from a map result is a patient who is already calling your competitor
• Calls are recorded only with proper notice and consent, since recording patient calls engages the Digital Personal Data Protection Act, 2023

An offer of a web booking path alongside the call is worth having, particularly for follow-ups and for younger urban patients. It is not the main event, and anyone pricing a project around it is solving the wrong constraint. This is the same misdiagnosis we see in lead generation generally — the funnel is blamed for a failure that happens at the front desk.

Can you still market to your patient database?

Only on consent obtained for that purpose.

Data collected to deliver care has not been consented to for marketing. Under the Digital Personal Data Protection Act, 2023, processing for a new purpose needs specific, informed consent for that purpose, and the October 2026 guidelines require advertising that involves processing digital personal data to comply with it.

In practice that rules out the standard chain playbook: exporting numbers from the clinic management system, uploading them as a custom audience, and running recall campaigns for annual check-ups. It does not rule out recall itself — a diagnostic chain reminding a diabetic patient that their test is due is clinically sensible and commercially valuable. It means the consent has to be captured at registration, separately, documented, and recorded against the patient record, and your audiences built only from the consented set.

Fix it at the front desk once and it compounds. Leave it and every retargeting campaign you run is a breach.

Is per-location optimisation really the best lever?

Three objections deserve a straight answer rather than a brush-off.

Compliance has a real cost, and I am not going to pretend otherwise. Review signals genuinely influence local prominence. A chain that stops soliciting reviews while competitors continue will lose map visibility to them, at least for a while. That is the honest trade: you are accepting a visibility cost to avoid an ethics proceeding against your doctors and a possible consumer-law exposure against the company. For a chain with registered practitioners whose licences are the business, that trade is usually right — the penalties under the guidelines run to suspension from the medical register. But it is a trade, not a free lunch, and any agency claiming compliance costs you nothing is selling.

Brand search does bypass local competition. For a chain with real recognition, a patient searching the brand plus "near me" is already yours, and top-of-funnel brand building may drive more per-centre volume than map optimisation. Fair — and it argues for doing both, with the proportion set by how known you actually are in each city. A chain entering a new city has no brand to harvest and nothing but the stack.

Referral drives the high-value patients. In ophthalmology, fertility, oncology and complex orthopaedics, referrals from general practitioners and secondary hospitals bring the highest-value cases. Local search tends to capture lower-ticket direct demand. This is true and it is a reason to run a structured referral programme alongside, not a reason to leave forty listings inaccurate.

What this looks like when Midgrow runs it

We would start with an audit nobody enjoys: every centre's listing, every duplicate, every wrong number, every wrong category, every practitioner title carrying a superlative, and every review campaign currently running. For most chains that produces a shutdown list before it produces a growth plan.

Then: the Location Integrity Stack built and maintained per centre, category architecture decided deliberately rather than inherited, location pages carrying factual capability for that centre, call routing and answer-rate measurement treated as part of the campaign, marketing consent captured properly at registration, and spend phased by centre maturity with a looser cost target for centres under three years.

On commercial terms, plainly: we work on a retainer. We do not price per patient or per lead, because engagements structured so that payment is linked to procuring or referring patients are prohibited. If an agency has quoted you a cost per footfall, that quote is the risk.

We are an AI-powered agency, and in this category the useful application is unglamorous: auditing and reconciling listing data across dozens of centres, generating per-centre location content at volume, and monitoring profiles for unauthorised edits. Not generating patients, faces or reviews — those uses are now prohibited outright.

Our companion piece on multi-specialty hospital marketing covers the institutional compliance regime and departmental demand in full, and the guide to local SEO for doctors covers the single-clinic case. This article is the chain problem.

If you run a specialty chain with more than three centres, your growth is currently limited by the worst-maintained listing in the network, and you probably do not know which one that is.

Talk to us. Book a consultation or message us on WhatsApp at +91 7415603507. Send your centre list and we will audit the listings before proposing anything. If the answer is that your data is already clean and the problem is your phones, we will tell you that instead.

This article summarises the regulatory position in general terms and is not legal advice. The NMC notice is on its own public notices page, and the review question in particular is one to settle with your own counsel.

Frequently asked questions

Can an Indian clinic ask patients for Google reviews after October 2026?

Treat it as legally doubtful rather than clearly permitted. The NMC guidelines state that a practitioner "shall not request or share patient testimonials," and separately bar soliciting fake, paid or misleading reviews. Whether a solicited genuine review counts as a testimonial is read differently by credible sources, so take your own legal view before continuing any review campaign.

What is clearly prohibited?

Requesting patient testimonials; soliciting, buying or manipulating fake, paid or misleading reviews; any incentive for a review; buying followers, likes or views; manipulating search rankings or algorithms; paid ranking of doctors on healthcare platforms; and paying an agency per lead or per patient.

Can we reply to reviews?

Replying is not itself barred, but keep replies general and non-clinical. Confirming that the reviewer was a patient, or discussing their condition, creates a patient-privacy exposure under the Digital Personal Data Protection Act, 2023 independently of the NMC position.

What happens if Google finds a review problem?

Google states it may remove the reviews and apply restrictions including blocking new reviews, unpublishing existing ones, and displaying a warning on the profile that fake reviews were removed. That warning is public and applies per location, which makes it worse than having no reviews at all.

Should each centre have its own Google Business Profile?

Yes — one verified, accurate, non-duplicated listing per centre, with the phone number ringing at that centre. Duplicate and conflicting listings are the dominant practical problem for chains that grew by acquisition, and they split the local signal between two pins.

How should we budget across new and mature centres?

Phase it by maturity. Dr Agarwal's FY25 disclosures show mature facilities over three years old contributing 70.7% of revenue against 29.3% from facilities under three years. A new centre should be allowed a worse cost per patient than a mature one, because the spend buys a local position rather than this month's bookings.

Is a website booking flow worth building?

Worth having, not worth leading with. Most Indian clinic appointments begin as a phone call from a map result, so answer rate, call routing and whether the person answering can actually book determine your conversion. There is no credible published Indian data on the exact split, so measure your own.

Can we run recall campaigns to past patients?

Only with marketing consent captured for that purpose. Clinical consent does not extend to promotional messaging under the DPDP Act, 2023, so uploading numbers from your clinic management system to build an audience is a breach unless a separate, documented consent exists. Capture it at registration.